Diluted virus was mixed with 3-fold dilutions of hF5-WT, LALA, or isotype control Ab for 1 hour and then used to inoculate Veros with 30 L per well. both Abs providing high levels of protection. However, when hF5-WT and hF5-LALA were administered + 48 h post contamination, there was a significant decrease in the therapeutic efficacy of hF5-LALA. Together these results demonstrate that optimal therapeutic Ab treatment of VEEV, and possibly other encephalitic alphaviruses, requires neutralization paired with engagement of immune effectors via the Fc region. KEYWORDS:Antibody dependent cell-mediated cytotoxicity (ADCC), antibody therapy, complement, complement dependent cytotoxicity (CDC), Fc effector function, Fc-engineering, neutralizing antibody, Venezuelan equine encephalitis computer virus (VEEV) == Introduction == The stochastic outbreaks of emerging pathogens such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provide a visceral sense of the urgency and importance of developing therapeutics that not only prevent computer virus infection, but also optimally engage the bodys immune defenses to clear infected cells.1,2Alphaviruses are members of the Togaviridae family and represent a class of emerging pathogens that can manifest in two clinical flavors: arthritogenic (e.g., chikungunya, CHIKV; Mayaro, MAYV; Ross River computer virus, RRV) and encephalitic (Venezuelan equine encephalitis computer virus, VEEV; Eastern equine encephalitis computer virus; Western equine encephalitis computer virus). Of particular concern as a potential bioweapon is usually VEEV, a category B select agent that can induce febrile illness, body aches, and inflammation of the central nervous system, leading to severe neurological symptoms or even death in equines and humans.3In addition, VEEV can be easily produced in large volumes and can spread by aerosol or transdermal inoculation (e.g., a mosquito bite). To mediate cell entry and initiate contamination, alphaviruses have two transmembrane glycoproteins E1 and E2 that form a heterodimer subunit arranged into 80 trimeric spikes around the virion. The main target of computer virus neutralizing antibodies (Abs) is the trimer uncovered on the surface of the virion, IDO-IN-3 with Rabbit polyclonal to FANK1 domain name A and B of E2 as the dominant targets of neutralizing Abs.48However, in infected cells the E1 and E2 proteins form a heterodimer on the surface of the cell in preparation for budding and several recent studies IDO-IN-3 have identified multiple potent, pan-protective anti-alphavirus monoclonal Abs that bind the E1 protein on the surface of infected cells and prevent virion budding.5,9,10Although several promising neutralizing and non-neutralizing monoclonal Abs have been identified, there is no approved vaccine or therapeutic to combat encephalitic alphaviruses.5,918 Ab-based protection against viral infections can be achieved by direct binding of Abs to viral proteins blocking computer virus entry (neutralization), blocking virion budding, and/or by effector functions conducted via the crystallizable fragment (Fc) of the Ab. Effector functions are mediated by conversation of the Fc with complement or Fc gamma receptors (FcRs) expressed on immune cells, facilitating clearance of infected cells, recruitment of immune cells to reservoirs of contamination, as well as other immunomodulatory functions. The three main Fc-mediated effector functions are Ab-dependent cell-mediated cytotoxicity (ADCC), Ab-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). ADCC and ADCP occur when the Fc domain name of Abs bound IDO-IN-3 to viral proteins on infected cells engage with FcRs on immune cells and either induce targeted cell death through the release of cytotoxic granules or promote the uptake of the infected cell or immune complex by phagocytosis. The Fc domain name of Abs bound directly to pathogen or infected cells can also elicit CDC through activation of the complement cascade, resulting in direct, localized lysis of infected cells and recruitment of immune effector cells through their complement receptors.19,20It was previously thought that prevention of computer virus cell entry through neutralization was the primary mechanism for Ab efficacy against viral infections, but recent studies are starting to demonstrate the critical role for Fc-mediated effector functions and virion egress inhibition as distinct modes of Ab-mediated protection against viral infections. For example, abrogation of Fc effector function leads to reduced serum half-life, affects bioavailability, and has been shown to diminish therapeutic efficacy in a variety of disease contexts including SARS-CoV-2, Mayaro computer virus, human immunodeficiency computer virus (HIV), Ebola computer virus, and Influenza.19,2131Even with these new findings there has been some reluctance to use Fc effector function-competent Abs as therapeutics due to the potential for FcR-mediated antibody-dependent enhancement of infection, whereby viruses take advantage of immune complexes to enter and infect immune cells, which is a particular concern for some flaviviruses. In addition to antibody-dependent enhancement of infection, the inflammatory response activated by immune complex interactions with FcRs may contribute to disease, so a balanced immune response is necessary for adequate protection and is critical to avoid.